DECIBEL THERAPEUTICS INC (DBTX) Stock Price & Overview
NASDAQ:DBTX • US24343R1068
Current stock price
The current stock price of DBTX is 4.91 USD. Today DBTX is down by -0.81%. In the past month the price decreased by -4.1%. In the past year, price increased by 28.53%.
DBTX Key Statistics
- Market Cap
- 123.388M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.53
- Dividend Yield
- N/A
DBTX Stock Performance
DBTX Stock Chart
DBTX Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to DBTX. When comparing the yearly performance of all stocks, DBTX is one of the better performing stocks in the market, outperforming 91.28% of all stocks.
DBTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to DBTX. DBTX may be in some trouble as it scores bad on both profitability and health.
DBTX Earnings
DBTX Forecast & Estimates
10 analysts have analysed DBTX and the average price target is 7.78 USD. This implies a price increase of 58.4% is expected in the next year compared to the current price of 4.91.
For the next year, analysts expect an EPS growth of -15% and a revenue growth -100% for DBTX
DBTX Groups
Sector & Classification
DBTX Financial Highlights
Over the last trailing twelve months DBTX reported a non-GAAP Earnings per Share(EPS) of -2.53. The EPS decreased by -9.05% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
DBTX Ownership
DBTX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.66 | 376.832B | ||
| AMGN | AMGEN INC | 15.42 | 188.135B | ||
| GILD | GILEAD SCIENCES INC | 15.77 | 169.255B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.03 | 112.576B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.53 | 79.215B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.35 | 41.92B | ||
| INSM | INSMED INC | N/A | 33.048B | ||
| BIIB | BIOGEN INC | 11.4 | 27.528B | ||
| NTRA | NATERA INC | N/A | 26.481B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.85 | 25.788B | ||
| MRNA | MODERNA INC | N/A | 19.048B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.372B | ||
| INCY | INCYTE CORP | 12.29 | 17.977B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About DBTX
Company Profile
Decibel Therapeutics, Inc. discovers and develops medicines to protect, repair, and restore hearing. The company is headquartered in Boston, Massachusetts and currently employs 68 full-time employees. The company went IPO on 2021-02-12. The firm is focused on discovering and developing transformative treatments for hearing and balance disorder. The company is focused on restoring and improving hearing and balance through the restoration and regeneration of functional hair cells and non-sensory support cells within the inner ear. The firm has built a platform that integrates single-cell genomics and bioinformatics analyses, precision gene therapy technologies and its proficiency in inner ear biology. The Company’s pipeline product includes its gene therapy program, namely DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin (OTOF) deficiency. In addition to its gene therapy product candidate and programs, it is also developing a clinical-stage product candidate, DB-020, for the prevention of cisplatin-induced hearing loss. Its products pipeline also includes AAV.103, AAV.104, DB-ATO and AAV.201.
Company Info
IPO: 2021-02-12
DECIBEL THERAPEUTICS INC
1325 Boylston Street, Suite 500
Boston MASSACHUSETTS 02215 US
CEO: Laurence Reid
Employees: 68
Phone: 16173708701.0
DECIBEL THERAPEUTICS INC / DBTX FAQ
Can you describe the business of DECIBEL THERAPEUTICS INC?
Decibel Therapeutics, Inc. discovers and develops medicines to protect, repair, and restore hearing. The company is headquartered in Boston, Massachusetts and currently employs 68 full-time employees. The company went IPO on 2021-02-12. The firm is focused on discovering and developing transformative treatments for hearing and balance disorder. The company is focused on restoring and improving hearing and balance through the restoration and regeneration of functional hair cells and non-sensory support cells within the inner ear. The firm has built a platform that integrates single-cell genomics and bioinformatics analyses, precision gene therapy technologies and its proficiency in inner ear biology. The Company’s pipeline product includes its gene therapy program, namely DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin (OTOF) deficiency. In addition to its gene therapy product candidate and programs, it is also developing a clinical-stage product candidate, DB-020, for the prevention of cisplatin-induced hearing loss. Its products pipeline also includes AAV.103, AAV.104, DB-ATO and AAV.201.
What is the stock price of DECIBEL THERAPEUTICS INC today?
The current stock price of DBTX is 4.91 USD. The price decreased by -0.81% in the last trading session.
Does DBTX stock pay dividends?
DBTX does not pay a dividend.
What is the ChartMill technical and fundamental rating of DBTX stock?
DBTX has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Is DECIBEL THERAPEUTICS INC (DBTX) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on DBTX.
Can you provide the growth outlook for DECIBEL THERAPEUTICS INC?
The Revenue of DECIBEL THERAPEUTICS INC (DBTX) is expected to decline by -100% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the market capitalization of DBTX stock?
DECIBEL THERAPEUTICS INC (DBTX) has a market capitalization of 123.39M USD. This makes DBTX a Micro Cap stock.